Skip to main content
. 2020 Nov 30;11:608248. doi: 10.3389/fendo.2020.608248

Table 1.

Anthropometric, demographic and metabolic features of post-RYGB patients according to glucose profile during the MMTT (Hypo and NoHypo).

MMTT result
Hypo NoHypo p value
N (% of total) 11 (47.8%) 12 (52.2%) NA
Sex (male/female) 2/9 2/10 1.000
Age at surgery (years) 40.6 (32.5-48.5) 45.2 (39.0-47.8) 0.294
History of T2DM before surgery (yes/no) 0/11 3/9 0.217
Follow-up time after surgery (years) 5.1 ± 0.6 3.8 ± 0.7 0.159
BMI before surgery (kg/m2) 40.1 ± 1.5 41.5 ± 1.6 0.527
BMI after surgery (kg/m2) 27.6 ± 0.7 28.5 ± 1.0 0.502
%EBMIL (%) 83.2 ± 4.0 81.9 ± 6.1 0.864
%TWL (%) 30.6 ± 2.1 31.0 ± 2.1 0.884
HbA1c (mmol/mol) 34.4 ± 1.3 35.8 ± 1.0 0.365
HbA1c (%) 5.3 ± 0.1 5.4 ± 0.1 0.358
HOMA2-B (%) 77.9 ± 6.7 70.1 ± 5.6 0.376
HOMA2-S (%) 144.2 ± 11.6 152.3 ± 15.6 0.685
HOMA2-IR 0.8 (0.6-0.8) 0.6 (0.5-1.0) 0.618
Self-reported hypoglycemia symptoms (yes/no) 7/4 7/5 1.000
Dumping criteria (yes/no) 11/0 10/2 0.478

Results are presented as mean ± SEM, median (interquartile range) or proportions. MMTT, mixed-meal tolerance test; Hypo, individuals developing a glucose nadir <3.05 mmol/l during the MMTT; NoHypo, subjects with glucose levels ≥3.05 mmol/l during MMTT; T2DM, type 2 diabetes mellitus; BMI, body mass index; EBMIL, excess BMI loss; TWL, total weight loss; HOMA2-B, homeostasis model assessment for β-cell function; HOMA2-S, homeostasis model assessment for insulin sensitivity; HOMA2-IR, homeostasis model assessment for insulin resistance.